Processa Pharmaceuticals Doses First Patient In Phase 2 Trial Of NGC-Cap For Metastatic Breast Cancer To Compare Safety-Efficacy Against Capecitabine And Determine Optimal Dosage Regimen
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals has initiated a Phase 2 trial for NGC-Cap, a treatment for metastatic breast cancer. The trial aims to compare the safety and efficacy of NGC-Cap against Capecitabine and determine the optimal dosage regimen.
October 02, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Processa Pharmaceuticals has dosed the first patient in a Phase 2 trial for NGC-Cap, targeting metastatic breast cancer. This trial will assess the safety and efficacy of NGC-Cap compared to Capecitabine and determine the optimal dosage.
The initiation of a Phase 2 trial is a significant milestone in drug development, indicating progress in the clinical testing of NGC-Cap. Positive results could enhance Processa's market position and potentially lead to increased stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100